Great Lakes Retirement Inc. Increases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Great Lakes Retirement Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 2,309 shares of the medical research company’s stock after purchasing an additional 115 shares during the period. Great Lakes Retirement Inc.’s holdings in IQVIA were worth $534,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. State Street Corp grew its position in shares of IQVIA by 2.5% during the second quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock valued at $1,899,660,000 after purchasing an additional 207,148 shares in the last quarter. Alliancebernstein L.P. grew its holdings in IQVIA by 19.1% during the 2nd quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after buying an additional 952,850 shares in the last quarter. Geode Capital Management LLC increased its stake in IQVIA by 2.2% in the 1st quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock worth $754,864,000 after acquiring an additional 81,501 shares during the last quarter. Lazard Asset Management LLC boosted its position in shares of IQVIA by 2.9% during the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock valued at $568,460,000 after acquiring an additional 80,189 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of IQVIA by 3.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after purchasing an additional 77,422 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.2 %

NYSE IQV traded up $0.38 on Thursday, hitting $252.95. The stock had a trading volume of 458,525 shares, compared to its average volume of 1,020,551. The business’s fifty day moving average price is $235.60 and its 200 day moving average price is $217.53. The stock has a market cap of $45.91 billion, a price-to-earnings ratio of 34.57, a price-to-earnings-growth ratio of 2.40 and a beta of 1.51. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same period in the previous year, the business earned $2.54 EPS. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Robert W. Baird lifted their price objective on shares of IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI increased their price target on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Finally, Truist Financial increased their target price on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

Insider Transactions at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock worth $10,331,003. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.